Generic placeholder image

Infectious Disorders - Drug Targets


ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Post Marketing Surveillance on Safety and Efficacy of IMOD in Iranian Patients with HIV/AIDS

Author(s): Minoo Mohraz, Abbas Sedaghat, SeyedAhmad SeyedAlinaghi, Hossein Asheri, Saeid Mohammaddoust, Farhad Gharibdoost, Hamid Reza Khorram Khorshid, Mohammad Farhadi, Seyed Hesamedin Madani and Koorosh Kamali

Volume 13, Issue 1, 2013

Page: [71 - 74] Pages: 4

DOI: 10.2174/18715265112129990031

Price: $65


Acquired Immune Deficiency Syndrome is one of the world's serious health problems. Immune-based therapy is a new approach in the treatment of HIV infected patients. IMODTM with the ability to correct immune deficiencies has been introduced for the management of HIV infection. In the phase IV trial study the main objectives were to assess the possible side effects, evaluate its effect on CD4+ T Lymphocyte count and patients’ and physicians’ satisfactions for 600 HIV infected patients in 13 centers during 2007. The observed adverse events in patients included: headache and vertigo (1.2%), nausea (1.2%), gastritis (1.2%), phlebitis (1%) and mild rash (1%); serious adverse events were not observed in any of IMODTM recipients. Therefore it was not needed to terminate the treatment in any of patient. The results of this study demonstrated that daily prescription of IMODTM significantly increases T Lymphocyte CD4+ and Total Lymphocyte Count in HIV-positive patients. In addition, nearly 90% of the patients and 70% physicians are satisfied by IMODTM treatment.

Keywords: Efficacy, IMODTM, post marketing surveillance, safety, satisfaction, side effect.

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy